1239034-62-8

Basic information

• Product Name: N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzamide trifluoroacetic acid salt
• Synonyms: N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzamide trifluoroacetic acid salt
• CAS NO: 1239034-62-8
• Molecular Weight: 449.43
• Mol File: 1239034-62-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzamide trifluoroacetic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzamide trifluoroacetic acid salt(1239034-62-8)
• EPA Substance Registry System: N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzamide trifluoroacetic acid salt(1239034-62-8)

Safety Data

• Hazardous Substances Data: 1239034-62-8(Hazardous Substances Data)

Upstream product

• 1252003-13-6 N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzamide 
• 76-05-1 trifluoroacetic acid 
• 1239034-71-9 4-(2-methyl-1,2,3,4-tetrahydro-β-carbolin-9-ylmethyl)benzoic acid methyl ester 
• 16502-01-5 tetrahydrobetacarboline 
• 13100-00-0 1,2,3,4-tetrahydro-2-methyl-9H-pyrido[3,4-b]indole 
• 1354547-63-9 tert-butyl 9-(4-(methoxycarbonyl)benzyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-carboxylate 
• 783293-89-0 methyl 4-((3,4-dihydro-1H-pyrido[3,4-b]indol-9(2H)-yl)methyl)benzoate 
• 168824-94-0 1,3,4,9-Tetrahydro-β-carboline-2-carboxylic acid tert-butyl ester 
• 1354547-65-1 N-hydroxy-4-((1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-9-yl)methyl)benzamide trifluoroacetate 
• 74-88-4 methyl iodide 

Relevant articles and documents

Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated

The discovery of isozyme-selective histone deacetylase (HDAC) inhibitors is critical for understanding the biological functions of individual HDACs and for validating HDACs as drug targets. The isozyme HDAC10 contributes to chemotherapy resistance and has

HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.